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Abstract
Background: Tumor tissue resembles chronically inflamed tissue. Since chronic inflammatory conditions are a
strong stimulus for bone marrow-derived cells (BMDCs) it can be assumed that recruitment of BMDCs into cancer
tissue should be a common phenomenon. Several data have outlined that BMDC can influence tumor growth and
metastasis, e.g., by inducing a paracrine acting feedback loop in tumor cells. Likewise, cell fusion and horizontal
gene transfer are further mechanisms how BMDCs can trigger tumor progression.
Results: Hygromycin resistant murine 67NR-Hyg mammary carcinoma cells were co-cultivated with puromycin
resistant murine BMDCs from Tg(GFPU)5Nagy/J mice. Isolation of hygromycin/puromycin resistant mBMDC/67NR-
Hyg cell clones was performed by a dual drug selection procedure. PCR analysis revealed an overlap of parental
markers in mBMDC/67NR-Hyg cell clones, suggesting that dual resistant cells originated by cell fusion. By contrast,
both STR and SNP data analysis indicated that only parental 67NR-Hyg alleles were found in mBMDC/67NR-Hyg
cell clones favoring horizontal gene transfer as the mode of origin. RealTime-PCR-array analysis showed a marked
up-regulation of Abcb1a and Abcb1b ABC multidrug transporters in mBMDC/67NR-Hyg clones, which was verified
by Western Blot analysis. Moreover, the markedly increased Abcb1a/Abcb1b expression was correlated to an
efficient Rhodamine 123 efflux, which was completely inhibited by verapamil, a well-known Abcb1a/Abcb1b
inhibitor. Likewise, mBMDCs/67NR-Hyg clones revealed a marked resistance towards chemotherapeutic drugs
including 17-DMAG, doxorubicin, etoposide and paclitaxel. In accordance to Rhodamine 123 efflux data,
chemotherapeutic drug resistance of mBMDC/67NR-Hyg cells was impaired by verapamil mediated blockage of
Abc1a/Abcb1b multidrug transporter function.
Conclusion: Co-cultivation of mBMDCs and mouse 67NR-Hyg mammary carcinoma cells gave rise to highly drug
resistant cells. Even though it remains unknown whether mBMDC/67NR-Hyg clones originated by cell fusion or
horizontal gene transfer, our data indicate that the exchange of genetic information between two cellular entities
is crucial for the origin of highly drug resistant cancer (hybrid) cells, which might be capable to survive
chemotherapy.
Background
It is known for decades that tumor tissue resembles
c h r o n i c a l l yi n f l a m e dt i s s u e-am a t t e rw h yt u m o r sh a v e
been referred to as “wounds that do not heal” [1,2].
Since chronic inflammation is a strong stimulus for the
recruitment of BMDCs [3-5] it can be concluded that
the migration of BMDCs into tumor tissues is a
common process.
Several lines of evidence indicated that BMDCs,
including macrophages and mesenchymal stem cells
(MSCs), can trigger tumor growth and metastasis [6-8].
It is assumed that BMDCs can promote a proglycolytic
phenotype in tumor cells, thus giving them a survival
advantage in hypoxic and inflammatory conditions [9],
or promote tumor cell survival through the activation of
the integrin-linked kinase (ILK), thereby activating the
prosurvival AKT signaling pathway [10]. Another
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colleagues by demonstrating that breast cancer cells sti-
mulated the de novo secretion of the chemokine CCL5
(also named RANTES) from MSCs, which then acted in
a paracrine fashion on the cancer cells to enhance their
motility, invasion and metastasis [7].
In addition to these mechanisms, which are based on
the intercellular communication between BMDCs and
tumor cells, cell fusion and horizontal gene transfer
(HGT) have also been associated with BMDC mediated
promotion of tumor growth and metastasis. Data of
Rizvi et al. indicated that BMDCs can fuse with neoplas-
tic intestinal epithelial cells, thereby giving rise to stable
tumor cell/BMDC hybrids [4]. Similar data were
recently provided by Powell and colleagues, whereby it
was shown that not only macrophages, but also T- and
B-cells can fuse with tumor cells [11]. Moreover, gene
expression analysis revealed a nuclear reprogramming in
hybrid cells [11]. Even though both studies did not
investigate whether BMDC/tumor cell hybrids do con-
tribute to tumor progression at all, several data of the
past years indicated that cell fusion is a common phe-
nomenon in cancer and that hybrid cells possess novel
characteristics, which can be definitely linked to tumor
progression (for review see [12,13]). These properties
include tissue heterogeneity [14,15], an increased malig-
nancy [16,17], drug resistance [12,16] and an enhanced
resistance of tumor cells to apoptosis [18]. Additionally,
cell fusion has also been suggested as one mechanism
how cancer stem cells might originate [13,19,20].
In contrast to animal studies, here it was shown that
BMDC × melanoma cell hybrids, either originated by
artificial in vitro cell fusion or by spontaneous in vivo
cell fusion, exhibited a markedly enhanced metastatic
capacity [21,22], the available data records for “cell
fusion in human tumors and the possible outcome” are
controversial. Putative cell fusion events have been
reported for renal cell carcinoma [23,24], breast cancer
[25,26], rectal cancer [27], and multiple myeloma
[28,29]. While data of Shabo and colleagues revealed
that expression of the macrophage receptor CD163 on
breast cancer and rectal carcinoma cells was generally
associated with a poorer outcome of afflicted patients,
Larsson et al. reported that syncytin expression constitu-
tes as a positive prognostic factor in breast cancer, pos-
sibly due to mediating fusions between breast cancer
cells and endothelial cells [30].
HGT has also been suggested as a mechanism how
tumor cells could receive foreign DNA concomitant
with rendering the cells malignancy (for review see:
[31]). Several lines of evidence indicated that HGT of
chromosomal DNA between tumor cells and tumor
cells or tumor cells and normal cells is efficiently facili-
tated through the uptake of apoptotic bodies [32]. HGT
of tumor DNA to endothelial cells in vivo gave rise to
endothelial cells maintaining the ability to form func-
tional vessels and concurrently express tumor-encoded
and endothelial-specific genes [33]. Likewise, in vivo
gene transfer between interacting human osteosarcoma
cell lines was associated with acquisition of an enhanced
metastatic potential [34].
I nt h ep r e s e n ts t u d yw ei n v e s t i g a t e dt h eo u t c o m eo f
co-cultivation of murine mammary 67NR-Hyg breast
cancer cells and murine BMDCs derived from Tg
(GFPU)5Nagy/J mice [35]. Our data show that
mBMDC/67NR-Hyg clones possessed a marked up-
regulation of Abcb1a/b ATP binding cassette (ABC)
multidrug resistance transporters, which was correlated
to an enhanced resistance of these cells towards che-
motherapeutic drugs.
Results
Co-cultivation of mBMDCs and murine 67NR mammary
carcinoma cells resulted in hygromycin and puromycin
double resistant cells
In the present study we investigated the co-cultivation
of mBMDCs and murine mammary carcinoma cells
(67NR-Hyg). The 67NR cell line was derived from a
mammary tumor, which spontaneously arose in a Balb/
cfC3H mouse [36]. It is highly tumorigenic, but not
metastatogenic [36,37]. To select for putative hybrid
cells, a dual antibiotic-based selection strategy [16,17,38]
was chosen. Thereby, mBMDCs exhibited EGFP expres-
sion and puromycin resistance [35], whereas murine
67NR-Hyg mammary carcinoma cells were stably trans-
fected with a hygromycin resistance. In total, 9 double
resistant clones (entitled as mBMDC/67NR-clone
X [X = 1-9]) were isolated and propagated. All clones
grew well in selection media. For further analysis clones
1 to 3 have been chosen randomly.
In order to prove whether these cell clones originated
from putative cell fusion events we first investigated for
the expression of parental marker molecules in
mBMDC/67NR-clones. Thereby, EGFP was used as
mBMDC marker, whereas for 67NR-Hyg cells the
hygromycin resistance gene was used. Figure 1 clearly
s h o w st h a tE G F Pw a se x p r e s s e di nm B M D C sa sw e l la s
in each mBMDC/67NR-clone, but not in parental
67NR-Hyg mammary carcinoma cells. By contrast, the
hygromycin resistance gene was clearly detected in mur-
ine 67NR-Hyg mammary carcinoma cells and all
mBMDC/67NR-clones, but not in mBMDCs (Figure 1).
In addition to PCR analysis of parental marker mole-
cules we additionally performed short-tandem-repeat
(STR) analyses and single nucleotide polymorphism
(SNP) analyses. STR analysis was performed for chro-
mosomes 4, 6, 12, 17, and 18, whereas SNP analysis was
carried out for chromosomes 1, 3, 5, 11, 13, 16. STR
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tional PCR since the lengths of the parental alleles were
large enough to separate them by conventional DNA
gel-electrophoresis. However, only the parental 67NR-
Hyg allele was found in all mBMDC/67NR-Hyg clones
(Additional File 1). Similar results were obtained for
STR analyses of chromosome 12. Both Tg(GFPU)5Nagy/
J mice and 67NR-Hyg mouse mammary carcinoma cells
possessed different alleles, but mBMDC/67NR-Hyg
clones 1-3 carried only the allele of the parental cancer
cell line (Additional File 1). By contrast, STR analyses
for chromosome 4, 6, and 18 showed that the parental
cells possessed identical alleles and thus a discrimination
was not feasible.
SNP analysis was informative for marker rs32800995
(chromosome 1), rs3022953 (chromosome 3), rs3023062
(chromosome 5), rs3088673 (chromosome 11), rs3023382
(chromosome 13), and rs3023435 (chromosome 16). Both
parental cell lines/strains carried the alleles as given in the
mouse genome information SNP database. However,
mBMDC/67NR-Hyg clones 1-3 had only alleles in com-
mon with the 67NR-Hyg mouse mammary carcinoma
cells (Additional File 2).
mBMDC/67NR-Hyg clones neither exhibited an increased
mean chromosomal number nor an increased
proliferation rate
Next the mean chromosomal number of mBMDC/
67NR-Hyg clones in relation to their parental cells was
analyzed. Of interest was the finding that the mean
chromosomal number of mBMDC/67NR-Hyg clones
was in between the mean chromosomal number of the
parental cells, namely 61 ± 19 (clone 1; Table 1), 66 ±
12 (clone 2; Table 1), and 50 ± 8 (clone 3; Table 1).
Analysis of the cell proliferation rate indicated that all
mBMDC/67NR-Hyg clones exhibited a slightly lower
proliferation rate than parental murine 67NR-Hyg can-
cer cells (Figure 2). Thereby, clone 2 showed the highest
proliferatory activity of all clones, whereas the relative
cell growth of clone 1 and clone 3 was nearly similar.
RealTime-PCR array data revealed a dramatic increase in
ABC multidrug transporters in mBMDC/67NR-Hyg clones
To investigate whether mBMDC/67NR-Hyg clones
exhibited an altered gene expression pattern as com-
pared to their parental cells a RealTime-PCR array
analysis was conducted by using the “Mouse Cancer
Drug Resistance and Metabolism” array. This array
covers 84 targets including genes for drug resistance,
drug metabolism, DNA repair, growth factor receptors,
and hormone receptors. For a better comparison
among the analyzed cell lines the gene expression
levels of mBMDC/67NR-Hyg clones and the 67NR-
Hyg cell line were calculated in the relation to the
gene expression pattern of mBMDCs, which was set to
1. The relative fold-changes of all analyzed genes are
s h o w ni nF i g u r e3 .
In accordance to previously published data [16] each
mBMDC/67NR-Hyg clone possessed a unique gene
expression pattern (Figure 3). Thereby, for some genes
o fas i n g l em B M D C / 6 7 N R - H y gc l o n et h er e l a t i v e
Figure 1 PCR analysis of parental cells and mBMDC/67NR-Hyg
clones. PCR analysis was performed to investigate whether
mBMDC/67NR-Hyg clones originated by cell fusion. EGFP, which
was used as a marker for mBMDCs, is expressed in mBMDCs and all
mBMDC/67NR-Hyg clones, but not in 67NR-Hyg mouse mammary
carcinoma cells. By contrast, the hygromycin resistance gene is
detectable in 67NR-Hyg mouse mammary carcinoma cells and
mBMDC/67NR-Hyg clones, but not in mBMDCs. In addition to EGFP
and hygromycin further molecules have been analyzed by PCR and
were found to be differentially regulated among parental cells and
mBMDC/67NR-Hyg clones.
Table 1 Mean chromosomal number of parental cells and
its mBMDC/67NR-Hyg clones
Cell line mean chromosomal number
BMDC 40 ± 0
67NR-Hyg 71 ± 12
clone 1 61 ± 19
clone 2 66 ± 12
clone 3 50 ± 8
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(e.g., Egfr: mBMDC: 1, clone 1: -114-fold, clone 2: -65-
fold, clone 3: -59-fold, 67NR-Hyg: -257-fold; Myc:
mBMDC: 1, clone 1: +21-fold, clone 2: +12-fold, clone
3: +18-fold, 67NR-Hyg: +50-fold), whereas for other
genes the appropriate expression levels were higher/
lower in single mBMDC/67NR-Hyg clone as compared
to parental cells (e.g., Esr1: mBMDC: 1, clone 1: -5-fold,
clone 2: -9-fold, clone 3: -22-fold, 67NR-Hyg: -3-fold).
Of particular interest was the finding that the expres-
sion levels of the ABC multidrug transporters Abcb1a
and Abcb1b were markedly increased in all clones as
compared to parental cells (Figure 3; Table 2). For
instance, the relative expression levels of Abcb1a and
Abcb1b were up to +626-fold and up to +113-fold in
clone 1 (Figure 3; Table 2). In order to verify RealTime-
PCR array data for Abcb1a/Abcb1b Western Blot analy-
sis was performed. Data are summarized in Figure 4 and
clearly depict the marked upregulation of Abcb1a/
Abcb1b in mBMDC/67NR-Hyg clones 1 to 3. Determi-
nation of the relative intensities of Abcb1a/b expression
levels in comparison to b-actin expression levels in
parental cells and hybrid cells nicely fitted to the Real-
Time-PCR array data (Figure 4).
In addition to EGFP (marker for mBMDCs) and
hygromycin resistance (marker for 67NR-Hyg), we
further analyzed the expression of Ccr7, Cxcr4, Cxcl12,
syncytin A (Syn A) and syncytin B (Syn B), and Slc1A5
i nb o t hp a r e n t a lc e l l sa sw e l la si na l lm B M D C / 6 7 N R -
Hyg clones. Ccr7 (binds Ccl19 and Ccl21) and Cxcr4
(binds Cxcl12 (also named stromal cell-derived factor
1a)) have been associated with the organ specific
metastatic spreading of breast cancer cells (for review
see [39]), while syncytin A, syncytin B and its receptor
Slc1A5 [25] have been linked to cell fusion
Ccr7 was expressed in parental 67NR-Hyg cells and
hybrid clone 3, but not in mBMDCs and clone 1 and 2
(Figure 1). By contrast, Cxcr4 was solely expressed in
mBMDCs and clone 3, but neither in 67NR-Hyg carci-
noma cells nor in clone 1 and 2 (Figure 1). Whether
this indicates that clone 3 may exhibit an enhanced cap-
ability to preferentially metastasize into regional lymph
nodes as well as, e.g., bone marrow or liver, remains to
be elucidated. Cxcl12 was solely expressed in mBMDCs
Figure 2 PCR analysis of parental cells and mBMDC/67NR-Hyg
clones. Proliferation of parental 67NR-Hyg mouse mammary
carcinoma cells, mBMDCs, and mBMDC/67NR-Hyg hybrid cell clones
1-3 was assessed by XTT-assay. Shown is the relative proliferation of
cells in relation to 24h values, which were set to 100%.
Figure 3 RealTime PCR analysis of parental cells and mBMDC/67NR-Hyg clones. Relative gene expression pattern of 67NR-Hyg mouse
mammary carcinoma cells, mBMDCs, and mBMDC/67NR-Hyg hybrid cell clones 1-3. Gene expression levels were determined by using the
“Mouse Cancer Drug Resistance and Metabolism” RealTime-PCR-array. The expression levels of the appropriate genes of the cancer cell line and
mBMDC/67NR-Hyg clones were calculated in relation to the expression level of the appropriate genes of mBMDCs, which were set to 0. Each
mBMDC/67NR-Hyg clone exhibits an unique gene expression profile. A difference in the gene expression level of greater than two-fold and less
than two-fold was considered as significant.
Table 2 ABC multidrug transporter expression
BMDC clone 1 clone 2 clone 3 67NR-Hyg
Abcb1a 1 626 373 566 8
Abcb1b 1 113 97 40 1
Abcc1 1 2 1 22
Abcc2 1 534 1
Abcc3 1 -28 -24 -94 -18
Abcc5 1 -1 -1 -2 2
Abcc6 1 1 33 1
Abcg2 1 -117 -79 -92 -200
Mvp 1 -2 1 -3 1
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for Syn A and Syn B as well as for their receptor
Slc1A5. Syn A and Syn B were markedly expressed in
mBMDCs and clone 3, whereas 67NR-Hyg predomi-
nantly expressed Syn A and only lower amounts of Syn
B (Figure 1). Clone 2 was negative for both Syn A and
Syn B, whereas clone 1 was weakly positive for Syn A
(Figure 1). Slc1a5 was expressed by 67NR-Hyg cells and
all three mBMDC/67NR-Hyg clones, whereas mBMDCs
were negative for this receptor (Figure 1).
Increased ABC multidrug transporter levels correlate with
a marked Rhodamine 123 efflux
In order to investigate whether the altered expression
levels of Abcb1a/Abcb1b and Abcg2 were associated
with a different phenotype of the cells, the efflux of
Rhodamine 123 was investigated. In accordance with
RealTime-PCR array data and Western Blot analysis
mBMDCs were not capable to efflux Rhodamine 123
indicated by a bright Rhodamine 123 staining (Figure 5).
By contrast, a slight population of weakly Rhodamine
123 stained 67NR-Hyg cells, the so-called side-popula-
tion (SP) fraction, was clearly detectable (Figure 5),
which is in accordance to RealTime-PCR array data
showing that Abcb1a was nearly 8-fold higher expressed
in 67NR-Hyg cells as compared to mBMDCs. Moreover,
inhibition of ABC multidrug transporter activity by vera-
pamil resulted in a markedly decreased 67NR-Hyg SP
fraction (Figure 5).
In contrast to parental cells the SP fraction was the
main population among mBMDC/67NR-Hyg clones,
whereby Rhodamine 123 was most efficiently effluxed
by clone 3. Here, nearly 88% of the cells showed low-
intensity fluorescence of Rhodamine 123 (Figure 5).
Inhibition of Abcb1a/b activity by verapamil comple-
tely blocked the Rhodamine 123 efflux in all clones
(Figure 5).
Increased ABC multidrug transporter levels correlate with
a resistance of clones towards chemotherapeutic
compounds
To investigate whether the markedly increased Abcb1a/
b expression levels were correlated to an increased resis-
tance of mBMDC/67NR-Hyg clones towards cytotoxic
compounds XTT cytotoxicity assays were carried out.
Thereby, mBMDC/67NR-Hyg clones and parental cells
were cultured for up-to three days in the presence of
different concentrations of 5-Fluorouracil (5-FU),
17-DMAG, doxorubicin, etoposide, and paclitaxel. Like-
wise, cells were cultured in the presence of 1 μMo ft h e
appropriate chemotherapeutic compound and 50 μM
verapamil to explore whether resistance was mediated
by Abcb1a/b multidrug transporters.
In accordance to previously published data [16]
mBMDC/67NR-Hyg clones did not exhibit an overall
resistance, but rather an enhanced resistance towards
certain chemotherapeutic drugs, including 17-DMAG,
doxorubicin, etoposide, and paclitaxel (Figure 6C, 6E,
6G, 6I). In contrast to this, mBMDC/67NR-Hyg clones
did not show an enhanced resistance towards 5-FU
(Figure 6A). Here, the survival rate of cells was comparable
to the survival rate of parental 67NR-Hyg cells
(Figure 6A). Interestingly, mBMDCs grew well in the pre-
sence of 5-FU without any dose-dependent cytotoxic effect
(Figure 6A). Inhibition of Abcb1a/b multidrug transporter
activity by verapamil had no effect on the proliferation
rate of hybrid cells and parental cells (Figure 6B) suggest-
ing that resistance of mBMDCs towards 5-FU is not
mediated by Abcb1a/b multidrug transporters.
By contrast, both mBMDCs and 67NR-Hyg mouse
mammary cancer cells showed a high susceptibility
towards 17-DMAG and doxorubicin (Figure 6C, 6E). In
case of 17-DMAG concentrations of 0.1 μM (mBMDCs)
and 0.5 μM (67NR-Hyg) were sufficient to effectively
kill all parental cells (Figure 6C). By contrast, the prolif-
eration of parental cells was impaired by doxorubicin in
a dose-dependent manner (Figure 6E). All mBMDC/
67NR-Hyg clones possessed a marked resistance towards
these two chemotherapeutic compounds (Figure 6C, 6E).
Concentrations of up to 5 to 10 μM 17-DMAG were
recommended to ultimately kill mBMDC/67NR-Hyg
clones (Figure 6C), whereas the proliferation of
mBMDC/67NR-Hyg cells was impaired by doxorubicin
in a dose-dependent manner (Figure 6E). Resistance of
cells towards both 1 μM 17-DMAG and doxorubicin
was significantly blocked by 50 μM verapamil suggesting
that the resistance of mBMDC/67NR-Hyg clones
towards these cytotoxic compounds is facilitated by
Abcb1a/b multidrug transporters (Figure 6D, 6F).
In accordance to 17-DMAG and doxorubicin,
mBMDC/67NR-Hyg clones also exhibited a marked
resistance towards etoposide (Figure 6G). Of interest
Figure 4 Western Blot analysis of Abcb1a/b expression. Western
Blot analysis was performed to verify Abcb1a/Abcb1b RealTime-PCR
data and clearly show that the ABC multidrug transporters were
markedly up-regulated in mBMDC/67NR-Hyg clones. The used
antibody recognizes both Abcb1 isoforms. b-actin served as a
loading control. Numbers indicate the relative Abcb1a/b expression
levels in relation to b-actin, whereby Abcb1a/b expression levels of
BMDCs were set to 100%.
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eration rate was slightly increased by this drug, whereby
a dose-dependent effect was not observed (Figure 6G).
Inhibition of Abcb1a/b multidrug transporter activity by
verapamil had only a partial effect (Figure 6H). Com-
pared to mBMDC/67NR-Hyg cells treated with 1 μM
etoposide growth of etoposide and verapamil co-treated
cells was solely, but significantly, decreased by about 50
to 60% (Figure 6H). This suggests that resistance of
mBMDC/67NR-Hyg clones towards etoposide was solely
partially facilitated by Abcb1a/b multidrug transporters.
We also observed a slight resistance of mBMDC/
67NR-Hyg cells towards paclitaxel, whereby the prolif-
eration rate of clone 1 and clone 2 within the presence
of different paclitaxel concentrations was comparable to
parental mBMDCs (Figure 6I). In contrast to this, clone
3 revealed a weaker resistance towards paclitaxel (Figure
6I). The differential resistance of mBMDC/67NR-Hyg
clones towards paclitaxel was also apparent when inhi-
biting Abcb1a/b multidrug transporter activity by vera-
pamil. In case of clone 1 and clone 2 resistance towards
paclitaxel was slightly significantly impaired by 50 μM
verapamil, whereas verapamil had no effect on the cell
growth of clone 3 within the presence of 1 μM pacli-
taxel (Figure 6J).
Discussion
In the present study we investigated the possible out-
come of co-cultivation of murine mammary 67NR-Hyg
breast cancer cells and murine BMDCs derived from Tg
(GFPU)5Nagy/J mice [35]. The rationale of this study
was given by the fact that tumor tissue resembles
chronically inflamed tissue (tumors are often described
as wounds that do not heal) [1,2,40] and that chronic
inflammation is a strong stimulus for the recruitment of
BMDCs [3-5]. This correlation suggests that the recruit-
ment of BMDCs into tumor tissues is a common
process.
Here, co-cultivation of murine BMDCs with 67NR-
Hyg mouse mammary carcinoma cells resulted in the
origin of cells exhibiting markedly increased expression
levels of the ABC multidrug resistance transporters
Abcb1a and Abcb1b concomitant with an enhanced
resistance towards chemotherapeutic drugs.
The finding that each of the analyzed mBMDC/67NR-
Hyg clones was positive for EGFP suggests that the
Figure 5 Rhodamine 123 is efficiently effluxed in mBMDC/67NR-Hyg clones. Rhodamine 123 efflux was assayed to prove whether Abcb1a/
Abcb1b up-regulation in mBMDC/67NR-Hyg clones was functional. Cells were loaded with Rhodamine 123 and analyzed for the remaining
cellular Rhodamine 123 content after 40 minutes by flow cytometry. The side-population (SP) population, representing cells, which have
effectively effluxed Rhodamine 123, are marked by an arrow. Verapamil was used to specifically block Abcb1a/Abcb1b multidrug transporters.
Flow cytometry data revealed that Rhodamine 123 is efficiently effluxed in mBMDC/67NR-Hyg clones; an effect, which was completely blocked
by verapamil.
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Page 6 of 13Figure 6 mBMDC/67NR-Hyg clones exhibit an enhanced resistance towards several chemotherapeutic drugs. XTT proliferation assay was
conducted to investigate whether the increased Abcb1a/Abcb1b expression levels of the mBMDC/67NR-Hyg clones were correlated with an
enhanced drug resistance. mBMDC/67NR-Hyg clones showed a marked resistance towards 17-DMAG and doxorubicin as well as etoposide and
paclitaxel, but not 5-Fluorouracil. Inhibition of Abcb1a/Abcb1b activity by verapamil completely blocked the doxorubicin resistance of mBMDC/
67NR-Hyg clones. By contrast, resistance of mBMDC/67NR-Hyg clones towards 17-DMAG, etoposide, and paclitaxel was partially impaired by
verapamil indicating that additional ABC transporters or other drug resistance mechanisms are involved in the mBMDC/67NR-Hyg clones
resistance towards these chemotherapeutic compounds.
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STR and SNP analyses revealed that only parental
67NR-Hyg alleles were present in mBMDC/67NR-Hyg
clones, thus facing the question whether mBMDC/
67NR-Hyg clones rather originated by horizontal gene
transfer (HGT). 67NR-Hyg cells might have uptaken
DNA containing microvesicles or apoptotic bodies
s h e d d e df r o mm B M D C s .I nar e c e n tw o r kE h n f o r sa n d
colleagues demonstrated in an in vivo setting that
endothelial cells can take up tumor cell DNA via HGT
[33] suggesting that a transfer of mBMDC DNA to
67NR-Hyg cells by HGT should be feasible. On the
other hand, HGT is a random process. It can not be
predicted which DNA fragments are embedded in
microvesicles/apoptotic bodies, which of these vesicles/
bodies will be uptaken by target cells and whether the
uptaken DNA will be ultimately incorporated into the
g e n o m eo ft h et a r g e tc e l l s .B e c a u s eo ft h a ti tr e m a i n s
ambiguous why all mBMDC/67NR-Hyg clones were
positive for EGFP.
Another argument which would favor HGT as the
mechanism of mBMDC/67NR-Hyg clone origin might
be the fact that the mean chromosomal number of the
clones was not the sum of the parental chromosomes.
The mean chromosomal number of mBMDC/67NR-Hyg
clones varied between 50 ± 8 to 66 ± 12 chromosomes,
which was rather half of the sum of the mean chromo-
somal number of the parental cells. In fact, recent stu-
dies demonstrated that cell fusion commonly went
along with a summation of parental chromosomes in
hybrid cells [16,17,41]. For instance, we have recently
demonstrated that breast epithelial/breast cancer hybrid
cells, which derived from spontaneous fusion events,
possessed a mean chromosomal number of 78 ± 11
(M13MDA435 clone 1) to 88 ± 13 (M13MDA435 clone
2), which was nearly the sum of the parental mean chro-
mosomal number [20]. On the contrary, the transition
of a hybrid cell from a heterokaryon (two nuclei) to a
synkaryon (one nucleus) is generally associated with a
loss of chromosomes [19]. Likewise, the aneuploid kar-
yotype of most hybrid cells is unstable and because of
that chromosomes are unequally segregated or even lost
during further cell divisions - a process, which has been
termed autocatalytic karyotypic evolution [42]. Another
possibility that could explain the phenomenon of a
reduced mean chromosomal number in mBMDC/67NR-
Hyg clone might be ploidy reduction [43]. This process
has been recently reported for murine fusion-derived
hepatocytes [43], whereby the mechanisms that direct
such a “meiosis-like” effect in somatic cells still remains
elusive. In any case, the authors observed a high degree
of marker loss in diploid daughter cells indicating that
ploidy reductions lead to the generation of highly
genetically diverse daughter cells with about 50%
reduction in nuclear content [43,44]. This dynamic
model of hepatocyte polyploidization, ploidy reversal
and aneuploidy (which has been referred to as “ploidy
conveyor”) has likely evolved to generate genetic diver-
sity, thereby permitting adaptation of hepatocytes to
xenobiotic or nutritional injury [44]. In context of our
study, such a mechanism would be a suitable explana-
tion for the finding that mBMDC/67NR-Hyg clones
possessed a reduced mean chromosomal number conco-
mitant with an increased drug resistance.
Thus, the question whether mBMDC/67NR-Hyg
clones ultimately originated by cell fusion or by HGT
can not be answered sufficiently. Both mechanisms are
conceivable. Recent data of Duncan et al. let assume
that the analyzed mBMDC/67NR-Hyg cells might have
originated by cell fusion accompanied by subsequent
ploidy reduction and autocatalytic karyotypic evolution.
Nonetheless, HGT can not be ruled out completely.
The cytotoxicity data presented here nicely fitted to
the ABC multidrug transporter expression levels of the
analyzed cells. Drug efflux is chiefly mediated by ABC
multidrug transporter(s), whereby a single drug can be
exported by several ABC multidrug transporters, and
each ABC multidrug transporter can confer characteris-
tics resistance pattern to cells [45]. By using the power
of combination knockout mice, being deficient for dis-
tinct murine ABC multidrug transporters, Lagas et al.
provided an update for murine ABC multidrug transpor-
ter and substrate specificities [46,47]. Thereby, etoposide
resistance is mediated by Abcb1a/b, Abcc1, Abcc2, and
Abcc3, whereas resistance to both doxorubicin and
paclitaxel is facilitated by Abcb1a/b and Abcc2 [46,47].
Thus the increased Abcb1a/b expression levels of
mBMDC/67NR-Hyg clones correlate well to the cells
resistance towards doxorubicin, which is further
strengthen by reverting the cells resistance with the
ABC1B (PGP/MDR1) inhibitor verapamil. Data showing
that resistance towards 17-DMAG (clone 1 and clone
3), etoposide and paclitaxel was solely partially blocked
by verapamil suggests that further ABC multidrug trans-
porter(s) or other mechanism do contribute to the cells
resistance towards these chemotherapeutic compounds.
Paclitaxel resistance has been associated with Abcb1a/b
and Abcc2 [47]. Since all mBMDC/67NR-hyg clones
possessed slightly higher Abcc2 expression levels and
Abcc2 has been reported to be the main transporter for
biliary excretion [47] it can be assumed that Abcc2 con-
tribute to paclitaxel resistance in the presence of verapa-
mil. By contrast, Abcb1a/b are the main transporters for
biliary excretion of doxorubicin, and Abcc2 only partly
compensates for the absence of Abcb1a/b [47], which
nicely correlates with the finding that doxorubicin resis-
tance of mBMDC/67NR-Hyg clones was completely
abrogated by verapamil. Likewise, etoposide resistance
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Abcc3 [46,47]. Since only Abcc2 was slightly higher
expressed in mBMDC/67NR-Hyg clones as compared to
parental murine 67NR-Hyg carcinoma cells, which
further correlates with the relative survival rates of
mBMDC/67NR-Hyg clones in comparison to 67NR-Hyg
cells, we conclude that etoposide is also effluxed by this
ABC multidrug transporter. Transfection of mouse
fibroblasts with murine Abcg2 resulted in an increased
etoposide resistance of the cells [48] suggesting that also
the increased Abcg2 levels in mBMDC/67NR-Hyg
clones might have contributed to the enhanced etopo-
side resistance.
In addition to the basal ABC multidrug resistance
transporter expression levels further mechanisms might
also contribute to the enhanced drug resistance of
mBMDC/67NR-Hyg clones. RealTime-PCR-array data
showed that several cytochrome p450 family members
were slightly higher expressed in mBMDC/67NR-Hyg
clones than in parental cells suggesting that drug inacti-
vation might be another mechanism. Likewise, due to
the aneuploid karyotype mBMDC/67NR-Hyg cells will
be able to adapt to the cytotoxic conditions. This
assumption is in view with preliminary data showing
that mBMDC/67NR-Hyg clones growing in 10 μMd o x -
orubicin exhibited an altered phenotype, such as an
increased cell diameter.
Conclusions
Our data indicate that co-cultivation of mBMDCs and
murine 67NR-Hyg mammary carcinoma cells can give
rise to highly drug resistant mBMDC/67NR-Hyg cells.
Even though it remains unknown whether these cells
originated by HGT or cell fusion our data might reflect
to the fatal impact of inflammation in the context of
cancer. Tumor tissue resembles chronically inflamed tis-
sues resulting in the recruitment of BMDCs. Moreover,
conventional cancer therapies, such as chemotherapy
and radiation, do also induce a strong inflammatory
response within the tumor tissues concomitant with
BMDC recruitment due to massive tumor cell destruc-
tion. Irrespective of how genetic information is
exchanged between two cells/two cell types: this process
could end in the evolution of a new cell/cell type exhi-
biting novel properties, such as an enhanced metastato-
genic capacity or an enhanced drug resistance.
Materials and methods
Cell culture and transfection
The murine mammary carcinoma cell line 67NR was
purchased from the American Tissue Culture Collection
(ATCC, LGC Standards GmbH, Wesel, Germany) and
was maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM, PAA, Linz, Austria) supplemented with 10%
fetal calf serum (FCS; PAA, Linz, Austria) and 1% Peni-
cillin/Streptomycin (100 U/ml Penicillin, 0.1 mg/ml
Streptomycin; PAA Laboratories, Linz, Austria) at 37°C
and 5% CO2 in a humidified atmosphere. Stable trans-
fection of 67NR cells with the pKS-Hyg plasmid was
done by electroporation using the AMAXA Nucleofec-
tor Technology (Lonza Cologne AG, Cologne, Germany)
in accordance to the manufacturers’ instructions. Hygro-
mycin resistant cells were selected by addition of 200
μg/ml Hygromycin B (PAA Laboratories, Linz, Austria)
to the media.
Murine bone marrow-derived cells (mBMDCs) were
obtained from the femurs of 8 - 9 week-old female
transgenic Tg(GFPU)5Nagy/J mice (Jackson Labora-
tories, Bar Habor, Maine, USA) expressing the enhanced
green fluorescent protein (EGFP) and the puromycin-
resistance gene [35]. Bone marrow cells were collected
by flushing the bone shaft with Iscove’s Modified Dul-
becco’s Medium (IMDM; PAA, Linz, Austria) using a
syringe and a 26G needle. The cell suspension was
seeded into a 75 cm
2 tissue culture flask and cultivated
for 24h in DMEM (PAA, Linz, Austria) supplemented
with 10% FCS (PAA, Linz, Austria) and 1% Penicillin/
Streptomycin (100 U/ml Penicillin, 0.1 mg/ml Strepto-
mycin; PAA Laboratories, Linz, Austria) at 37°C and 5%
CO2 in a humidified atmosphere. Subsequently, non-
adherent cells were removed and the remained
mBMDCs were cultivated for additional two weeks.
C e l l sw e r ep a s s a g e do n c ep r i o rf o rt h e i ru s ei n
experiments.
Co-cultivation of mBMDC and 67NR-Hyg mammary
carcinoma cell
Murine BMDCs (1 × 10
6) and 67NR-Hyg mouse mam-
mary cancer cells (1 × 10
6) were co-cultivated for 24h in
DMEM (PAA, Linz, Austria) supplemented with 10%
FCS (PAA, Linz, Austria) and 1% Penicillin/Streptomy-
cin (100 U/ml Penicillin, 0.1 mg/ml Streptomycin; PAA
Laboratories, Linz, Austria) without Hygromycin and
Puromycin at 37°C and 5% CO2 in a humidified atmo-
sphere. After 24h both antibiotics were added to the
media (Hygromycin B: 200 μg/ml; Puromycin: 5 μg/ml;
Puromycin was purchased from Sigma Aldrich, Tauf-
kirchen, Germany). Double resistant clones were first
analyzed for a green fluorescence, then isolated and cul-
tivated separately from each other. Isolated clones were
named as mBMDC/67NR-clone-X, whereby “X” marks
the clone number.
RT-PCR
RNA was isolated from 1 × 10
6 cells by using the
NucleoSpin
® RNA II Kit (Macherey-Nagel GmbH,
Düren, Germany) in accordance to the manufacturers’
instructions. Reverse Transcription of RNA into cDNA
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TM First Strand
cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany)
as referred to the instruction manual. PCR was per-
formed in a 25 μl reaction mixture containing 1.25U
Taq Polymerase, 1 × reaction buffer, 2 mM MgCl2, 200
μM of each dNTP (all reagents were purchased from
Fermentas, St. Leon-Rot, Germany) and 100 pM primers
(Invitrogen, Karlsruhe, Germany). The cycling condi-
tions comprised of an initial denaturation of 5 min at
94°C and 30 cycles of 0.5 min at 94°C, 0.5 min at the
appropriate annealing temper a t u r ea n d0 . 5m i na t7 2 ° C
followed by a final elongation for 10 min at 72°C. The
used primer pairs concomitant with their specific
annealing temperature and product lengths are summar-
ized in Table 3.
Short tandem repeat (STR) and Single nucleotide
polymorphism (SNP) analysis
Genomic DNA was extracted by using the NucleoS-
pin
® Tissue Kit (Macherey-Nagel GmbH, Düren, Ger-
many) in accordance to the manufacturers’
instructions. Amplificationo fD N Af r a g m e n t sf o rS T R
and SNP analysis was performed by conventional PCR
according to above-mentioned protocol, whereby 25 ng
genomic DNA were used as a template. Suitable STRs
and SNPs for analysis were determined in accordance
to the mouse genome information strains, SNPs &
polymorphisms database (http://www.informatics.jax.
org/strains_SNPs.shtml) and the genetic quality control
annual report (http://jaxmice.jax.org/geneticquality/
gqcreport.pdf). The used primer pairs and product
lengths are summarized in additional file 3 and addi-
tional file 4. For STR analysis PCR products (1 μl)
were mixed with 9.5 μlH i - D i
TM Formamide and 0.5 μl
GeneScan™-500 LIZ
® size standard (Applied Biosys-
tems, Darmstadt, Germany) in a 96-well microtiter
plate. After heating the loading cocktail for 3 min at
95°C samples were immediately chilled on ice. Samples
were analyzed by capillary electrophoresis for 2,500s by
using a 3130 × l ABI PRISM Genetic Analyzer
(Applied Biosystems, Darmstadt, Germany). Data ana-
lysis was performed with the GeneMapper (v 4.0) soft-
ware (Applied Biosystems, Darmstadt, Germany). For
SNP analysis PCR products were purified with the
QIAquick
®PCR purification kit (QIAGEN, Hilden,
Germany) as recommended. PCR products (1-10 ng)
were sequenced with the BigDye
®Terminator v1.1
Cycle Sequencing Kit (Applied Biosystems, Darmstadt,
Germany) in accordance to the manufacturer’si n s t r u c -
tions. Not incorporated labeled ddNTPs were removed
with the DyeEx
® 2.0 spin kit (QIAGEN, Hilden, Ger-
many) as described in the manual. Purified sequencing
products were analyzed by using a 3130 × l ABI
PRISM Genetic Analyzer (Applied Biosystems, Darm-
stadt, Germany). Data analysis was performed with the
ABI PRISM 3130 data collection software (Applied
Biosystems, Darmstadt, Germany) and the ClustalW2-
Multiple Sequencing Alignment tool (European Bioin-
formatics Institute, Wellcome Trust Genome Campus,
Hinxton, UK).
Table 3 Summary of primer pairs for PCR
Name Annealing temperature Mean product size Primer Sequence (5’ to 3’)
Ccr7 61°C 208 bp forward AGCACCATGGACCCAGGGA
reverse CTGCCTCTCATGTATTCTGT
Cxcr4 57°C 390 bp forward GGCTGTAGAGCGAGTATTGC
reverse GTAGAGGTTGGTGACAGTGTAGAT
Cxcl12 61°C 512 bp forward ACACTCCGCCATAGCATATGGT
reverse TGAAGCATGCGTTTGGAGG
EGFP 61.5°C 220 bp forward GACAAGCAGAAGAACGGCATCAAG
reverse CGGCGGCGGTCACGAACT
HYG 60.5°C 500 bp forward AGCTGCGCCGATGGTTTCTACAA
reverse ATCGCCTCGCTCCAGTCAATG
Syn A 60°C 281 bp forward TACCTGATGCGCCTGGAGCT
reverse AAGCTTTGCAGGAACTGGAGAA
Syn B 60°C 201 bp forward CCACCACCCATACGTTCAAA
reverse GGTTATAGCAGGTGCCGAAG
Slc1a5 59°C 585 bp forward CTGGATTATGTGGTACGCCAC
reverse GACCTGTCCACTAGCCAGTC
Dhfr 59°C 159 bp forward CCACAACCTCTTCAGTGGAAGGTAAACAGA
reverse TTGGCAAGAAAATGAGCTCCTCGTGG
Gapdh 68°C 980 bp forward TGAAGGTCGGTGTGAACGGATTTGGC
reverse CATGTAGGCCATGAGGTCCACCAC
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Cells (1 × 10
6)w e r ec u l t i v a t e dw i t h0 . 2μg/ml colcemid
(Sigma Aldrich, Taufkirchen, Germany) for 4 - 6h. Sub-
sequently, cells were harvested, washed once with PBS,
and were carefully resuspended in 10 ml 75 mM KCl.
After 30 min the cells were sedimented (160 × g, 10
min) and the supernatant was discarded. Cells were
carefully resuspended in the remaining KCl solution.
Hereafter, 10 ml methanol/acetic acid solution (3:1;
both chemicals were purchased from Sigma Aldrich,
Taufkirchen, Germany) was added dropwise under con-
tinuous stirring to the cells. Cells were then washed at
least twice in methanol/acetic acid solution. Finally, the
methanol/acetic acid fixed cells were dropped onto a
H2O wetted cover slip. To visualize spread chromoso-
mal DNA cover slips were air-dried and subsequently
stained with Sytox Green (Invitrogen, Karlsruhe, Ger-
many) as recommended to the manufacturers’ instruc-
tions combined with confocal laser scanning microscopy
(Leica TCS SP5; Leica, Bensheim, Germany).
RealTime-PCR
RNA was isolated from 2-4 × 10
6 cells by using the
NucleoSpin
® RNA II Kit from Macherey-Nagel
(Macherey-Nagel GmbH, Düren, Germany) in accor-
dance to the manufacturers’ instructions. Reverse Tran-
scription of RNA into cDNA was performed using the
RT
2 First Strand Kit (QIAGEN GmbH, Hilden, Ger-
many) as referred to the instruction manual. In this
study, the RT
2Profiler
TM PCR Array “Mouse Cancer
Drug Resistance and Metabolism” (QIAGEN GmbH,
Hilden, Germany) covering 84 genes was applied by
using an Applied Biosystems 7700 RealTime-PCR cycler
(Applied Biosystems, Darmstadt, Germany). RealTime-
PCR was performed using the RT
2 SYBR Green Master
Mix (QIAGEN GmbH, Hilden, Germany) according to
the manufacturers’ protocol under the following cycler
conditions: 95°C: 10 min; 40 Cycles (95°C: 15s; 60°C:
60s). RealTime-PCR data were analyzed by the 2
-ΔCT
method on a Microsoft
TM Excel
® template provided by
the manufacturer (QIAGEN GmbH, Hilden, Germany).
Significant changes in gene expression among the ana-
lyzed cell lines were defined as at least 2-fold up- or
downregulation of genes.
Western Blot
Western Blot analysis
To verify RealTime-PCR data for Abcb1a and Abcb1b
expression cells (5 × 10
5) were lysed in SDS sample buf-
fer for 1h at 36°C. Subsequently, samples were separated
by SDS-PAGE on a 8% SDS polyacrylamide gel and
transferred to PVDF membranes (Millipore, Schwalbach,
Germany) under semi-dry conditions. Membranes were
blocked overnight with 10% (w/v) non-fat dry milk in
TBS-T. Abcb1a/Abcb1b and b-actin were detected by
using the following primary antibodies: MDR (Abcb1a/
Abcb1b; clone C-19; Santa Cruz Biotechnology, Heidel-
berg, Germany) and b-actin (clone 13E5; rabbit mono-
clonal, Cell Signaling, New England Biolabs, Frankfurt
am Main, Germany). For detection of primary antibodies
the HRP-conjugated secondary anti-rabbit IgG (Cell Sig-
naling, New England Biolabs, Frankfurt am Main, Ger-
many) was used. Bands were visualized using the
LumiGLO
® Reagent (Cell Signaling, New England Bio-
labs, Frankfurt am Main, Germany) in accordance to the
manufacturers’ instructions and were detected with the
Aequoria Macroscopic Imaging system (Hamamatsu
Photonics Germany, Herrsching am Ammersee, Ger-
many). Relative densities of Abcb1a/b expression in rela-
tion to b-actin was determined by using the ImageJ
software (http://rsb.info.nih.gov/ij/).
Flow cytometry
The efflux of Rhodamine 123 (Sigma Aldrich Tauf-
kirchen, Germany) was analyzed by using a FACScalibur
flow cytometer (Becton Dickenson, Heidelberg, Ger-
many). Cells (5 × 10
5) were incubated in PBS containing
200 μg/ml Rhodamine 123, 50 μM verapamil (Sigma
Aldrich Taufkirchen, Germany), or a combination of
both for 20 min at 37°C. Thereafter, cells were washed
once with PBS and incubated for additional 20 min at
37°C. Rhodamine 123 fluorescence was detected using
the FL1-H channel.
XTT cytotoxicity assay
The XTT cytotoxicity assay was performed as
described [49] with slight modifications. In brief, cells
(1 × 10
3/well) were seeded in triplicates in a 96-well
flat-bottom microtiter plate in 0.25 ml of the appropri-
ate culture medium. After 24 h media was replaced by
culture media containing different concentrations of
either 5-Fluorouracil (5-FU), 17-DMAG, doxorubicin,
etoposide or paclitaxel (all drugs were purchased from
Sigma Aldrich, Taufkirchen, Germany). In case of vera-
pamil, 1 μM of the appropriate chemotherapeutic drug
was used alone or in combination with 50 μM verapa-
mil (Sigma Aldrich, Taufkirchen, Germany). After 48h
media was removed and the plates were analyzed with
XTT reagent (Roche Diagnostics, Mannheim, Ger-
many) according to the manufacturer’s instructions.
The absorption of the formed XTT-formazan deriva-
tive was measured using a BioTek EL800 microplate
reader (BioTek, Bad Friedrichshall, Germany). The
EGFP fluorescence of mBMDCs and mBMDC/67NR-
Hyg hybrids did not interfere with the XTT-formazan
formed derivative. Statistical significance was calcu-
lated using Student’s t-test: n.s. = not significant; * =
P < 0.05; ** = P <0 . 0 1 ;* * *=P < 0.001;
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Additional file 1: Figure S1: STR analysis of mBMDC/67NR-Hyg
clones. A) STR analysis of chromosome 17 by conventional PCR. Only
the parental 67NR-Hyg allele was found in mBMDC/67NR-Hyg clones.
Fragment lengths are indicated. B) Result of STR analysis of
chromosomes 4, 6, 12, and 18 by capillary electrophoresis. Parental cells
were homozygote for chromosome 4, 6 and 18 and heterozygote for
chromosome 12. However, only the parental 67NR-Hyg chr. 12 allele was
present in mBMDC/67NR-Hyg clones.
Additional file 2: SNP analysis of mBMDC/67NR-Hyg clones. Primer
sequences appear in blue. Known polymorphisms are shown in red,
whereas unknown polymorphisms are marked in green. SNPs located on
chromosome 1, 3, 5, 11, 13 and 16 were analyzed. However, only the
parental 67NR-Hyg SNPs were present in mBMDC/67NR-Hyg clones.
Additional file 3: Summary of primer pairs for STR analysis
Additional file 4: Summary of primer pairs for SNP analysis
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